Published in Maturitas on September 25, 2003
Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med (2002) 3.17
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab (2010) 2.27
Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation (2002) 2.18
Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci U S A (2006) 1.79
International versions of the Menopause Rating Scale (MRS). Health Qual Life Outcomes (2003) 1.70
The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes (2004) 1.62
Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. J Cardiovasc Med (Hagerstown) (2009) 1.44
Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J Clin Invest (2002) 1.40
IMS updated recommendations on postmenopausal hormone therapy. Climacteric (2007) 1.20
Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS One (2008) 1.14
Estrogen receptor-alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol (2010) 1.12
Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS One (2008) 1.08
Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J (2007) 1.07
HRT in the early menopause: scientific evidence and common perceptions. Climacteric (2008) 1.05
The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study. Health Qual Life Outcomes (2004) 1.03
Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas (2008) 1.00
Extra-nuclear signaling of estrogen receptors. IUBMB Life (2008) 0.98
Progesterone receptor enhances breast cancer cell motility and invasion via extranuclear activation of focal adhesion kinase. Endocr Relat Cancer (2010) 0.97
EMAS position statement: Managing the menopause in the context of coronary heart disease. Maturitas (2010) 0.97
Rapid regulatory actions of sex steroids on cell movement through the actin cytoskeleton. Steroids (2008) 0.96
Compensatory feto-placental upregulation of the nitric oxide system during fetal growth restriction. PLoS One (2012) 0.95
Effects in postmenopausal women of estradiol and medroxyprogesterone alone and combined on resistance artery function and endothelial morphology and movement. J Clin Endocrinol Metab (2008) 0.95
Rapid signaling of estrogen to WAVE1 and moesin controls neuronal spine formation via the actin cytoskeleton. Mol Endocrinol (2009) 0.95
Effect of climacteric transition and hormone replacement therapy on body weight and body fat distribution. Gynecol Endocrinol (2006) 0.93
EMAS position statement: Vitamin D and postmenopausal health. Maturitas (2011) 0.92
Progestogens regulate endothelial actin cytoskeleton and cell movement via the actin-binding protein moesin. Mol Hum Reprod (2008) 0.90
EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy. Maturitas (2012) 0.89
Lung cancer during pregnancy involving the products of conception and a review of the literature. Arch Gynecol Obstet (2002) 0.89
EMAS clinical guide: assessment of the endometrium in peri and postmenopausal women. Maturitas (2013) 0.88
Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion. BMC Cancer (2008) 0.87
Controversial issues in climacteric medicine I. Cardiovascular disease and hormone replacement therapy. International Menopause Society Expert Workshop. 13-16 October 2000, royal society of medicine, London, UK. Climacteric (2000) 0.87
Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists. J Agric Food Chem (2008) 0.87
Oestrogen and progestins differently prevent glutamate toxicity in cortical neurons depending on prior hormonal exposure via the induction of neural nitric oxide synthase. Steroids (2009) 0.86
EMAS position statement: Managing women with premature ovarian failure. Maturitas (2010) 0.86
17β-estradiol induces vasorelaxation by stimulating endothelial hydrogen sulfide release. Mol Hum Reprod (2012) 0.85
Estrogen regulates endometrial cell cytoskeletal remodeling and motility via focal adhesion kinase. Fertil Steril (2010) 0.85
The European Menopause Survey 2005: women's perceptions on the menopause and postmenopausal hormone therapy. Gynecol Endocrinol (2006) 0.85
EMAS position statement: managing obese postmenopausal women. Maturitas (2010) 0.85
Why sex matters: the biological mechanisms of cardiovascular disease. Gynecol Endocrinol (2012) 0.84
Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril (2010) 0.84
EMAS position statement: Managing menopausal women with a personal or family history of VTE. Maturitas (2011) 0.84
Timing is everything. Gynecol Endocrinol (2007) 0.84
A functioning FSH-secreting pituitary macroadenoma causing an ovarian hyperstimulation syndrome with multiple cysts resected and relapsed after leuprolide in a reproductive-aged woman. Gynecol Endocrinol (2011) 0.83
Progesterone enhances vascular endothelial cell migration via activation of focal adhesion kinase. J Cell Mol Med (2012) 0.83
Are risk factors common to thyroid cancer and nodule? A forty years observational time-trend study. PLoS One (2012) 0.83
Clinical management of breast cancer in males: a report of four cases. Eur J Obstet Gynecol Reprod Biol (2002) 0.83
Non-genomic sex steroid actions in the vascular system. Semin Reprod Med (2007) 0.82
Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol (2014) 0.82
Effects of raloxifene on breast cancer cell migration and invasion through the actin cytoskeleton. J Cell Mol Med (2009) 0.82
Sex steroids and breast cancer metastasis. Horm Mol Biol Clin Investig (2010) 0.82
Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol (2012) 0.81
Estrogen receptor-{alpha} promotes endothelial cell motility through focal adhesion kinase. Mol Hum Reprod (2010) 0.80
The metabolic syndrome and its components in postmenopausal women. Gynecol Endocrinol (2013) 0.80
Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas (2005) 0.79
The female pelvic floor through midlife and aging. Maturitas (2013) 0.79
Hormonal influence on the central nervous system. Maturitas (2002) 0.79
Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. J Obstet Gynaecol Res (2014) 0.79
Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. Maturitas (2002) 0.79
Cytoarchitecture modifications of the human uterine endocervical mucosa in long-term three-dimensional organotypic culture. Pathol Res Pract (2005) 0.79
Feto-placental nitric oxide, asymmetric dimethylarginine and vascular endothelial growth factor (VEGF) levels and VEGF gene polymorphisms in severe preeclampsia. J Matern Fetal Neonatal Med (2012) 0.79
Assessment of insomnia and related risk factors in postmenopausal women screened for the metabolic syndrome. Maturitas (2012) 0.79
Extra-nuclear signaling of ERalpha to the actin cytoskeleton in the central nervous system. Steroids (2009) 0.79
Presence of a putative steroidal allosteric site on glycoprotein hormone receptors. Eur J Pharmacol (2009) 0.79
A three-dimensional organotypic culture of the human uterine exocervix for studying mucosal epithelial differentiation and migrating leukocytes. Differentiation (2004) 0.79
EMAS position statement: managing the menopause in women with epilepsy. Maturitas (2010) 0.78
Hormone therapy. Menopause (2003) 0.78
Feto-placental vascular dysfunction as a prenatal determinant of adult cardiovascular disease. Intern Emerg Med (2013) 0.78
Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Contraception (2007) 0.78
More data on hormone therapy and coronary artery disease: comments on recent publications from the WHI and Nurses' Study. Climacteric (2006) 0.77
[Management of cardiovascular risk in the peri-menopausal woman--a consensus statement of European cardiologists and gynaecologists]. Kardiol Pol (2007) 0.77
EMAS position statement: Bone densitometry screening for osteoporosis. Maturitas (2010) 0.77
Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions. J Clin Endocrinol Metab (2010) 0.77
EMAS position statement: Managing the menopause in women with a past history of endometriosis. Maturitas (2010) 0.77
Pharmacotherapy: Benefits of menopausal hormone therapy--timing is key. Nat Rev Endocrinol (2012) 0.77
Clinical characteristics and genetic analysis in women with premature ovarian insufficiency. Maturitas (2012) 0.77
The latest elaboration of the Women's Health Initiative data on hormone replacement therapy and cardiovascular disease in postmenopausal women. Gynecol Endocrinol (2007) 0.77
Effects of progesterone and medroxyprogesterone on actin remodeling and neuronal spine formation. Mol Endocrinol (2013) 0.77
Sex steroids and their receptors: molecular actions on brain cells. Gynecol Endocrinol (2012) 0.76
Nitric oxide and pro-inflammatory cytokine serum levels in postmenopausal women with the metabolic syndrome. Gynecol Endocrinol (2012) 0.76
Clinical relevance of the HERS trial. Lancet (2002) 0.76
Hormone therapy and cardiovascular disease in the early postmenopause: the WHI data revisited. Climacteric (2007) 0.76
Polymorphisms of the methylenetetrahydrofolate reductase gene (C677T and A1298C) in nulliparous women complicated with preeclampsia. Gynecol Endocrinol (2014) 0.76
Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007. Gynecol Endocrinol (2007) 0.75
EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis. Maturitas (2011) 0.75
From the challenge to the reassessment of the Women's Health Initiative: a personal initiative for women's health. Gynecol Endocrinol (2006) 0.75
Recommendations on the management of fragility fracture risk in women younger than 70 years. Gynecol Endocrinol (2012) 0.75
Estrogen regulates endothelial migration via plasminogen activator inhibitor (PAI-1). Mol Hum Reprod (2012) 0.75
Hard stuff for the bones. Menopause (2012) 0.75
Vasomotor symptoms and negative affect: time to act. Menopause (2011) 0.75
EMAS position statement: Late parenthood. Maturitas (2013) 0.75
Effects of red clover extracts on breast cancer cell migration and invasion. Gynecol Endocrinol (2011) 0.75
The International Society of Gynecological Endocrinology and its president. Gynecol Endocrinol (2012) 0.75
17β-estradiol attenuates atherosclerosis development: the possible role of hydrogen sulfide. Int J Cardiol (2012) 0.75
The progesterone and estrogen modify the uterine prolactin and prolactin receptor expression of hyperprolactinemic mice. Gynecol Endocrinol (2014) 0.75
ISGE statement on oral emergency contraception. Gynecol Endocrinol (2014) 0.75
Urinary tract infections in diabetic women during menopause: new basis for a multidisciplinary approach. Pol Arch Intern Med (2017) 0.75
WHI and breast cancer: a response to a recent publication from the WHI. Climacteric (2006) 0.75